Private Advisor Group LLC Sells 6,557 Shares of GSK plc (NYSE:GSK)

Private Advisor Group LLC cut its holdings in shares of GSK plc (NYSE:GSKFree Report) by 8.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,419 shares of the pharmaceutical company’s stock after selling 6,557 shares during the quarter. Private Advisor Group LLC’s holdings in GSK were worth $2,610,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares in the last quarter. BKM Wealth Management LLC acquired a new position in shares of GSK during the 4th quarter worth about $32,000. Larson Financial Group LLC increased its stake in shares of GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 647 shares during the last quarter. Jones Financial Companies Lllp increased its stake in shares of GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the last quarter. Finally, Princeton Global Asset Management LLC increased its stake in shares of GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after purchasing an additional 533 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Morgan Stanley assumed coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Get Our Latest Report on GSK

GSK Stock Up 0.9 %

Shares of GSK opened at $45.07 on Friday. GSK plc has a 52 week low of $33.33 and a 52 week high of $45.10. The firm has a market cap of $93.40 billion, a P/E ratio of 16.33, a price-to-earnings-growth ratio of 1.90 and a beta of 0.65. The firm’s 50-day simple moving average is $42.08 and its 200 day simple moving average is $39.43. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.3762 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.34%. This is a positive change from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio is 57.61%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.